semaglutide

Semaglutide is a long-acting, selective, competitive GLP-1R agonist and a long-acting analog of human glucagon-like peptide-1, exhibiting potent hypoglycemic, weight-loss, cardioprotective, and neuroprotective effects. Upon activation of the GLP-1R, semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, while also enhancing autophagy and suppressing oxidative stress and apoptosis. Semaglutide also plays a role in regulating mitochondrial function and lipid metabolism. Semaglutide is being investigated for use in type 2 diabetes, obesity, Parkinson’s disease, metabolic and fatty liver diseases (MASLD), and other neurodegenerative and liver diseases, as well as in cancer research.

Semaglutide TFA is a glucagon-like peptide-1 congener that induces weight loss, lowers blood glucose levels, and reduces cardiovascular risk in diabetic patients.Semaglutide TFA induces mild-to-moderate and transient gastrointestinal disturbances, and may be used in the study of type 2 diabetes and obesity.

Semaglutide-13C6,15N trifluoroacetic acid isotopes, is a form of Semaglutide trifluoroacetic acid. This compound is a long-acting, selective, competitive, orally active GLP-1R agonist capable of crossing the blood-brain barrier. Upon GLP-1R activation, it stimulates insulin secretion, inhibits gastric emptying and appetite, and enhances autophagy while reducing oxidative stress and apoptosis (apoptosis). Additionally, it modulates mitochondrial function and lipid metabolism, such as reducing hepatic de novo lipogenesis. Semaglutide trifluoroacetic acid exhibits activities including blood glucose reduction, weight loss, neuroprotection (such as improving motor function in Parkinson’s disease models and reducing α-synuclein aggregation), and amelioration of hepatic steatosis. It is useful for research into type 2 diabetes, obesity, Parkinson’s disease, metabolic-associated steatotic liver disease (MASLD), other neurodegenerative conditions, liver diseases, and cancer.

Semaglutide-d8tetraTFA is a deuterium-labeled form of Semaglutide. Semaglutide is a long-acting, selective, competitive GLP-1 receptor agonist that crosses the blood-brain barrier. Upon activating the GLP-1 receptor, it enhances insulin secretion, suppresses gastric emptying and appetite, and improves mitochondrial function and lipid metabolism (such as reducing hepatic de novo lipogenesis). It offers antihyperglycemic, weight-reduction, neuroprotective (such as improving motor function in Parkinson's disease models and reducing α-synuclein aggregation), and hepatosteatosis amelioration effects. It is applicable in research on type 2 diabetes, obesity, Parkinson’s disease, metabolic-associated steatotic liver disease (MASLD), and certain neurodegenerative and liver diseases, as well as cancer.

Semaglutide (FITC-labeled Semaglutide) is a long-acting analog of human glucagon-like peptide-1, functioning as an agonist of the GLP-1 receptor. It shows potential for research related to type 2 diabetes.

Semaglutide Acetate is a GLP-1R agonist (EC50=6.2 pM) with long-acting, selective, competitive, and oral efficacy. Semaglutide acetate can be used in the study of type 2 diabetes.

Semaglutide sodium is a glucagon-like peptide-1 (GLP-1) receptor agonist that exerts its blood glucose-lowering effect by mimicking GLP-1. It promotes pancreatic beta-cell function and insulin secretion while inhibiting glucagon release, thereby reducing hepatic glycogenolysis and gluconeogenesis. In addition, Semaglutide sodium slows gastric emptying and reduces appetite, thereby decreasing energy intake and promoting weight loss.

Semaglutide-D8 Tetratrifluoroacetate is a deuterated compound of Semaglutide Tetratrifluoroacetate.

Semaglutide-d8 is the deuterium-labeled form of Semaglutide. Semaglutide, a long-acting, selective, competitive GLP-1R agonist, can cross the blood-brain barrier. Upon GLP-1R activation, it promotes insulin secretion, inhibits gastric emptying and appetite, and enhances autophagy while suppressing oxidative stress and apoptosis. It also regulates mitochondrial function and lipid metabolism, such as reducing hepatic de novo lipogenesis. Semaglutide exhibits activities like lowering blood glucose, weight reduction, neuroprotection (e.g., improving motor function in Parkinson’s models and reducing α-synuclein aggregation), and amelioration of hepatic steatosis. It is used in the research of type 2 diabetes, obesity, Parkinson’s disease, metabolic-associated steatotic liver disease (MASLD), other neurodegenerative diseases, liver disorders, and cancer.

(S)-5-(tert-Butoxy)-4-(18-(tert-butoxy)-18-oxooctadecanamido)-5-oxopentanoic acid is an intermediate used in the synthesis of various active compounds.

Vensemaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, utilized in research related to diabetes or other metabolic disorders.